MétaCan
Menu
Back to cohort

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

2025· article· en· W4416968887 on OpenAlexaff
Reid W. Merryman, Sarah C. Rutherford, Stephen M. Ansell, Philippe Armand, John P. Leonard, Loretta J. Nastoupil, Sonali M. Smith, John M. Timmerman, Andrew D. Zelenetz, Meghan Gutierrez, Wendy Béguelin, Carla Casulo, James R. Cerhan, Michael R. Green, Brad S. Kahl, Robert Kridel, Brian K. Link, Matthew J. Maurer, Bertrand Nadel, Andrea J. Radtke, Efrat Luttwak, Gilles Salles, Laurie H. Sehn, Laura Pasqualucci, Ann S. LaCasce

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsSpinal Cord Injury BCUniversity of British ColumbiaPrincess Margaret Cancer Centre
FundersNational Cancer InstitutePharmacyclicsGenentechNational Institutes of HealthIncyteGilead SciencesRegeneron PharmaceuticalsLeukemia and Lymphoma SocietyIpsenBeiGeneDaiichi Sankyo EuropeSanofiPfizerNational Institute of Allergy and Infectious DiseasesMorphoSysCelgeneAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsFollicular lymphomaLymphomaContext (archaeology)Clinical trialDiseaseChemotherapyFollicular phase

Abstract

fetched live from OpenAlex

ABSTRACT: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.057
metaresearch head score (Gemma)0.092
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.057
Threshold uncertainty score0.301

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0570.092
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.007
Bibliometrics0.0050.004
Science and technology studies0.0030.002
Scholarly communication0.0080.006
Open science0.0090.006
Research integrity0.0260.020
Insufficient payload (model declined to judge)0.0350.026

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.305
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicLymphoma Diagnosis and TreatmentFrench-language works237,207